Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Kashiyama, Tomoko ^a   Oda, Katsutoshi ^a   Ikeda, Yuji ^a   Shiose, Yoshinobu ^b   Hirota, Yasuhide ^b   Inaba, Kanako ^a   Makii, Chinami ^a   Kurikawa, Reiko ^a   Miyasaka, Aki ^a   Koso, Takahiro ^a   Fukuda, Tomohiko ^a   Tanikawa, Michihiro ^a   Shoji, Keiko ^a   Sone, Kenbun ^a   Arimoto, Takahide ^a   Wada Hiraike, Osamu ^a   Kawana, Kei ^a   Nakagawa, Shunsuke ^c   Matsuda, Koichi ^d   McCormick, Frank ^e   Aburatani, Hiroyuki ^f   Yano, Tetsu ^g   Osuga, Yutaka ^a   Fujii, Tomoyuki ^a   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TOKYO   (Japan)

^g NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DS 7423; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; MESSENGER RNA; MTOR PROTEIN, HUMAN; P53AIP1 PROTEIN, HUMAN; PHOSPHOSERINE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL POPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; IC 50; MOUSE; NONHUMAN; OVARIAN CLEAR CELL ADENOCARCINOMA; OVARY ADENOCARCINOMA; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TUMOR VOLUME; ADENOCARCINOMA, CLEAR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PHOSPHOSERINE; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895102985     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087220     Document Type: Article

References (53)

1. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-510.
2. Jia S, Liu Z, Zhang S, Liu P, Zhang L, et al. (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454: 776-9.
3. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, et al. (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 105: 13057-13062.
4. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.
5. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
6. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734.
7. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22. (Pubitemid 47001784)
8. Mayo LD, Donner DB (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98: 11598-11603. (Pubitemid 32928774)
9. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
10. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, et al. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030.
11. Cao P, Maira SM, Garcia Echeverria C, Hedley DW (2009) Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 100: 1267-1276.
12. Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, et al. (2012) Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One 7: e37431.
13. Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG (2011) Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, Gynecol Oncol 2010. 121: 407-415.
14. Takano M, Tsuda H, Sugiyama T (2012) Clear cell carcinoma of the ovary: is there a role of histology-specific treatment? J Exp Clin Cancer Res 31: 53-59.
15. Bell D, Berchuck A, Birrer M, Chien J, Cramer D, et al. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615. Cancer Genome Atlas Research Network.
16. Ho ES, Lai CR, Hsieh YT, Chen JT, Lin AJ, et al. (2001) p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol 80: 189-193.
17. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, et al. (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174: 1597-1601.
18. Munksgaard PS, Blaakaer J (2012) The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol 124: 164-169.
19. Fujimura M, Katsumata N, Tsuda H, Uchi N, Miyazaki S, et al. (2002) HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res 93: 1250-1257. (Pubitemid 36032989)
20. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, et al. (2011) Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol 24: 1146-1155.
21. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, et al. (2012) Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. Mod Pathol 25: 122-130.
22. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC (2004) Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10: 1032-1042. (Pubitemid 39625247)
23. Bono Y, Kyo S, Takakura M, Maida Y, Mizumoto Y, et al. (2012) Creation of immortalised epithelial cells from ovarian endometrioma. Br J Cancer 106: 1205-1213.
24. Minaguchi T, Yoshikawa H, Oda K, Ishino T, Yasugi T, et al. (2001) PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 7: 2636-2642. (Pubitemid 32911365)
25. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554. (Pubitemid 38541907)
26. Oda K, Stokoe D, Taketani Y, McCormick F (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669-10673. (Pubitemid 41713332)
27. Oda K, Okada J, Timmerman L, Rodriguez Viciana P, Stokoe D, et al. (2008) PIK3CA cooperates with other phosphatidylinositol 39-kinase pathway mutations to effect oncogenic transformation. Cancer Res 68: 8127-8136.
28. Nakagawa S, Yoshikawa H, Jimbo H, Onda T, Yasugi T, et al. (1999) Elderly Japanese women with cervical carcinoma show higher proportions of both intermediate-risk human papillomavirus types and p53 mutations. Br J Cancer 79: 1139-1144. (Pubitemid 29087887)
29. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, et al. (2000) p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862.
30. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, et al (1997) 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11. (Pubitemid 127376388)
31. Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, et al (1999) Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 18: 2892-2900. (Pubitemid 29250879)
32. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, et al (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404: 42-49. (Pubitemid 30143125)
33. Kortlever RM, Higgins PJ, Bernards R (2006) Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 8: 877-884.
34. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, et al (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120. (Pubitemid 44040989)
35. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, et al (2010) Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A 107: 7461-7466.
36. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, et al. (2010) The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 16: 3628-3638.
37. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508. (Pubitemid 43259931)
38. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940. (Pubitemid 46474636)
39. Takano M, Kikuchi Y, Kudoh K, Goto T, Furuya K, et al. (2011) Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases. Int J Clin Oncol 16: 605-609.
40. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299. (Pubitemid 27220766)
41. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, et al. (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 277: 21843-21850. (Pubitemid 34952337)
42. Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-694. (Pubitemid 32706359)
43. Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y, et al. (2002) p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 62: 2883-2889. (Pubitemid 34525775)
44. Vousden KH, Prives C (2009) Blinded by the Light: The Growing Complexity of p53. Cell 137: 413-421.
45. Fu Z, Tindall DJ (2008) FOXOs, cancer and regulation of apoptosis. Oncogene 27: 2312-2319. (Pubitemid 351501782)
46. Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, et al. (2009) The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood 114: 4507-4516.
47. Letai A (2006) Growth factor withdrawal and apoptosis: the middle game. Mol Cell 21: 728-730.
48. Koul D, Fu J, Shen R, LaFortune TA, Wang S, et al (2012) Antitumor activity of NVP-BKM120- a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18: 184-195.
49. Jeong SJ, Dasgupta A, Jung KJ, Um JH, Burke A, et al (2008) PI3K/AKT inhibition induces caspase-dependent apoptosis in HTLV-1-transformed cells. Virology 370: 264-272. (Pubitemid 350199679)
50. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, et al. (2008) Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 3: e3065.
51. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, et al. (2010) Predictive biomarkers of sensitivity to the phosphatidylinositol 39 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16: 3670-3683.
52. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, et al. (2009) Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69: 143-150.
53. Petitjean A, Achatz MI, Borresen Dale AL, Hainaut P, et al. (2005) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26: 2157-2165. (Pubitemid 46536647)